PTSD

The therapy is the first self-neuromodulation device for PTSD approved by the US Food and Drug Administration.

Here are some updates from the world of psychiatry throughout the month of February.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

The treatment's PDUFA date is set for August 11, 2024.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

Here are some updates from the world of psychiatry throughout the month of January.

The experts weighed in on a wide variety of psychiatric issues for the January 2024 issue of Psychiatric Times.

From substance use disorders in physicians to new research on the efficacy of MDMA-assisted therapy for PTSD, here are highlights from the week in Psychiatric Times.

Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.

What can we learn from war trauma?

In a first of its kind study, MDMA-assisted therapy successfully supported patients with PTSD.

Here are 5 processes to provide focus and empowerment for patients with PTSD.

From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.

What is new in research on posttraumatic stress disorder?

The device is now available at 2 US clinics, with training and installation currently underway at several other locations.

Here are some updates from the world of psychiatry throughout the month of December.

Initial data from phase 2 safety profile for psilocybin in the treatment of PTSD indicates the treatment is well-tolerated.

MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.

What is new in research on psychedelics?

The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.

From long-acting injectable antipsychotics for managing schizophrenia to mental health responses to the recent conflict in Israel, here are highlights from the week in Psychiatric Times.

Concurrent treatments targeting eating disorders and PTSD are needed to help these patients with complex conditions.

Residues of past traumatic events can deeply impact our present experiences and our functioning in ways that we are not aware of consciously. We must process and let go of these experiences in order to heal.

Climate change plays a pivotal role in the recent surge of wildfires, and their impact on mental health. How can you, as a clinician, help those impacted by these disasters, specifically children and adolescents?

New data from the Suicide and Trauma Reduction Initiative for Veterans at Ohio State University indicates the most effective interventions to prevent suicide risk among veterans.

Psychiatry will be needed to help heal the mental wounds in the Mideast.

Here are some updates from the world of psychiatry throughout the month of September.

The ongoing clinical trial is also studying the drug’s efficacy in the treatment of MDD.

"For months she has dreamed in red..."